| Revision as of 02:27, 15 March 2023 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,831 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper← Previous edit | Latest revision as of 20:57, 1 December 2023 edit undoBuidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,068 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot | ||
| Line 58: | Line 58: | ||
| ] | ] | ||
| ] | ] | ||
| {{antiinfective-drug-stub}} | {{antiinfective-drug-stub}} | ||
| {{monoclonal-antibody-stub}} | {{monoclonal-antibody-stub}} | ||
Latest revision as of 20:57, 1 December 2023
Monoclonal antibody Pharmaceutical compound| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Clumping factor A |
| Clinical data | |
| Trade names | Aurexis |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6548H10122N1730O2034S44 |
| Molar mass | 147035.72 g·mol |
| (what is this?) (verify) | |
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis and of methicillin-resistant S. aureus.
It was developed by Inhibitex.
See also
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
References
- Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
- Pan A, Lorenzotti S, Zoncada A (January 2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-Infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
- John JF (October 2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Current Opinion in Molecular Therapeutics. 8 (5): 455–60. PMID 17078388.
| Monoclonal antibodies for infectious disease and toxins | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fungal |
| ||||||||
| Viral | |||||||||
| Bacterial |
| ||||||||
| Toxin |
| ||||||||
| |||||||||
 | This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |